Bivalirudin versus Heparin Monotherapy in Myocardial Infarction
Why the study?
Does bivalirudin reduce the composite of death, myocardial infarction, or major bleeding in patients undergoing PCI for myocardial infarction compared to heparin monotherapy?
Population
Patients undergoing PCI for myocardial infarction
Comparison
Bivalirudin vs Heparin monotherapy
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Bivalirudin does not reduce the composite endpoint versus heparin in MI PCI; reinforces heparin monotherapy as standard and challenges routine bivalirudin preference.
Structured PICO
Does bivalirudin reduce the composite of death, myocardial infarction, or major bleeding in patients undergoing PCI for myocardial infarction compared to heparin monotherapy?
P
Population
Patients undergoing PCI for myocardial infarction
I
Intervention
Bivalirudin
C
Comparator
Heparin monotherapy
O
Outcome
Composite of death from any cause, myocardial infarction, or major bleedingcomposite
In patients undergoing PCI for myocardial infarction, bivalirudin does not provide a significant advantage over heparin monotherapy for the composite of death, MI, or major bleeding.
Cite This Study
Erlinge et al. (2017) studied this question.